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The potential of magnetic hyperthermia for
triggering the diﬀerentiation of cancer cells
Sandhya Moise, *a,b James M. Byrne, c Alicia J. El Hajb,d and Neil D. Telling b
Magnetic hyperthermia is a potential technique for cancer therapy
that exploits heat generated by magnetic nanoparticles to kill can-
cerous cells. Many studies have shown that magnetic hyperthermia
is eﬀective at killing cancer cells both in vitro and in vivo, however
little attention has been paid to the cellular functioning of the
surviving cells. We report here new evidence demonstrating the
onset of thermally triggered diﬀerentiation in osteosarcoma cancer
cells that survive magnetic hyperthermia treatment. This raises the
possibility that in addition to causing cell death, magnetic
hyperthermia could induce surviving cancer cells to form more
mature cell types and thereby inhibit their capacity to self-renew.
Such processes could prove to be as important as cell death when
considering magnetic hyperthermia for treating cancer.
Magnetic nanoparticles (MNPs) can remotely transduce external
field energy into thermal energy. This property of the MNPs to
induce local heating under the influence of an alternating mag-
netic field, known as magnetic hyperthermia, has been exploited
in various biomedical applications.1–3 In particular magnetic
hyperthermia is being explored as a method for treating tumours
in cancer therapy. By functionalizing the MNP surface with
cancer-cell specific antigens and by applying a suitable high fre-
quency alternating magnetic field (typically 50–1000 kHz) to the
region of interest, it is possible to precisely target and eliminate
cancer cells without aﬀecting healthy tissue.4,5
At temperatures higher than 41 °C, the survival rate of
mammalian cells decreases with increasing exposure time.6,7
Magnetic hyperthermia adopts such an approach and triggers
heat-related cell death to eliminate cells within a cancerous
tumour. While much current research is focussing on develop-
ing advanced particles with excellent heating properties and
studying their eﬀect on cell viability following hyperthermia,8,9
there is very little understanding of other responses of the
cancer cells to the treatment.
Chemical, spatial and physical cues, including temperature
have been shown to aﬀect cellular behaviour. For instance,
such cues have been shown to trigger the maturation of stem
cells towards more specialized cell types, a phenomenon
known as diﬀerentiation.10–15 Both in embryonic and adult
stem cells, studies have found evidence of mild heat-shock
aﬀecting cellular proliferation and diﬀerentiation.11,16–18 Both
single and repetitive heat-shock treatments were found to
trigger diﬀerentiation down various lineages such as chondro-
(cartilage) and osteogenic (bone).10,11 In osteogenic diﬀeren-
tiation (bone-forming), heat-shock was found to enhance the
production of the enzyme alkaline phosphatase (ALP), an early
marker for osteogenesis.11,17
Diﬀerentiation therapy is an emerging research field for
treating cancer where the aim is to cause diﬀerentiation of
tumour cells so as to decrease their proliferative capacity. This
therapy is targeted towards a subset of cancer cells that can
self-renew, referred to as cancer stem cells (CSC). Their unre-
gulated self-renewal property is considered to drive the growth
and spread of the tumour.19,20 CSCs could arise from malig-
nant transformation of normal stem cells or due to progenitor
cells acquiring the ability to continuously self-renew.21
Channelling these cells to diﬀerentiate into more mature phe-
notypes results in a reduction of their self-renewal capacity,
similar to their non-transformed stem cell-counterparts.22
In this study we assessed the eﬀect of heat-shock from mag-
netic hyperthermia treatment on cancer cells, focusing on the
fate of the surviving cells. For this, we used a bone-cancer cell-
line (MG-63)23,24 as our model system and determined both
cell viability and diﬀerentiation state following the treatment.
MG-63 cells have been used as a model cell line for assessing
various cancer drugs and cancer therapies including diﬀeren-
tiation therapy using retinoic acid.25 Unlike their healthy
osteoblastic counterparts, these cells are not terminally diﬀer-
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entiated and only show basal levels of expression of osteogenic
markers such as RUNX2, Osterix or ALP.26–28 Following
hyperthermia treatment we assessed changes in their diﬀeren-
tiation state by measuring the degree of up-regulation of ALP.
For bone-related cells such as the MG-63 cells, an increased
expression of ALP indicates commitment to diﬀerentiate down
the osteogenic (bone) lineage.29,30
For this study we used citric acid coated zinc doped magne-
tite nanoparticles (Zn0.4Fe2.6O4) to produce heat via magnetic
hyperthermia, as they were found previously to show the stron-
gest magnetic response in cellular environments (as measured
via AC susceptometry) compared to similar particles,31 and
with citric acid coating show minimal cytotoxicity at the con-
centrations of interest.32 The citric acid coating also ensures
that the MNPs remain stably suspended, thus allowing hom-
ogenous heating of the entire sample volume.
In order to expose cells to a uniform temperature we devel-
oped an approach based on MNP extracellular heating. In this
approach, cells grown as monolayers on sterile PLA films were
placed vertically into 5 ml sample tubes (Fig. 1a) and comple-
tely immersed in cell-culture media that was pre-loaded with
stably suspended MNPs. A sterile fiber optic temperature
probe was also immersed into the solution in order to
measure the media temperature in situ. The sample tubes were
placed at the centre of a coil in a custom built magnetic
hyperthermia instrument. In the case of the 37 °C control, the
sample tube containing cells and nanoparticles was placed in
the magnetic hyperthermia instrument for 30 min without
turning on the magnetic field. In this case, the cooling water
in the coil was set such that the ambient temperature in the
sample volume was 37 °C. For the heat treated samples, cells
were exposed to a 30 min magnetic hyperthermia treatment at
time point zero, with a repeated treatment performed at
48 hours. After each treatment the cells were removed and
placed in fresh MNP-free media to avoid interactions between
the cells and MNPs that could influence cell behaviour.
Results
Prior to the cellular experiments the optimum field conditions
required to maximise the heating power of the MNPs were
determined. This was done by measuring the heating of the
aqueous suspensions of the MNPs. The heating power (i.e. the
specific loss power, also known as the specific absorption rate)
was measured at diﬀerent field strengths and frequencies as
shown in Fig. 1b. The combination of field strength and fre-
quency parameters were limited due to the limitations of the
coil-capacitor combination compatible with our hyperthermia
instrument. At 29.4 mT and 362 kHz, the citric acid-coated
Zn0.4Fe2.6O4 nanoparticle suspension showed a maximum
heating response, as reflected by its specific loss power value
(SLP) of 182 W g−1 (Fig. 1b). We chose this magnetic field fre-
quency for all the cellular experiments, but controlled the mag-
netic field strength by adjusting the coil voltage in order to
reach target temperatures of 42 °C for mild heat-shock, and
47 °C for severe heat-shock in the solutions which the cells
were immersed in. An example measurement for this is shown
in Fig. 1c.
The changes in morphology of the cells following the
hyperthermia treatment at 0 and after the repeated treatment
at 48 hours, were observed by bright-field imaging, as shown
in Fig. 2. Cells were imaged at 24, 72 and 120 hours after the
start of the experiment. The MG-63 cells are adherent cells
Fig. 1 (a) Schematic showing the set-up for cellular magnetic hyperthermia experiments. Monolayer of cells grown on PLA ﬁlms were placed vertically
into a solution of 10% v/v MNP containing cell-culture media. An optical probe was immersed into this solution to measure temperature in situ. (b)
Measured Speciﬁc Loss Power (SLP) values of aqueous suspensions of Zn0.4Fe2.6O4 nanoparticles at diﬀerent ﬁeld frequencies (184–843 kHz). (c) In
situ temperature measurements during cellular magnetic hyperthermia using the optical thermal probe, using a magnetic ﬁeld of 29.4 mT at 362 kHz.
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with a well-defined triangular morphology. This can be
observed clearly for the cells maintained at 37 °C (Fig. 2a)
which are seen to proliferate and increase in confluence at the
later time-points. For the cells heated to 42 °C by hyperther-
mia, although a majority of the cells are viable at 24 hours fol-
lowing the first treatment (Fig. 2d), a significant population of
detached cells can be seen after the second treatment at the
72 hours time point (Fig. 2e). By 120 hours this sample shows
stress-related changes in the cellular morphology such as
shrinkage as well as rounding up with minimal or no cells left
attached (Fig. 2e and f). For the strongest heat-shock treated
sample (47 °C), loss in a healthy morphology is observed even
after a single treatment (Fig. 2g). Very few cells remain at
further time points following the second treatment (Fig. 2h
and i).
To assess osteogenic diﬀerentiation, the expression of the
enzyme alkaline phosphatase was measured on these samples
at various time points (Fig. 3). Fig. 3a shows the total DNA
content (quantified using the PicoGreen™ assay) as a pro-
portional measure of cell numbers33 for each of the sample at
the diﬀerent time points. While no significant diﬀerence is
observed between the 37 °C sample and 42 °C until 72 hours,
at 120 hours significant decrease in cell numbers is observed
as also perceived in the micrographs (Fig. 2). At the highest
heat-shock condition of 47 °C a qualitative reduction in cell
number is seen by 24 hours, but this only becomes significant
by 72 hours and beyond.
Fig. 3b shows the total ALP expression of the samples as
measured using the 4-MU assay. At each time point of
measurement, the ALP measurements reflect the trend
observed for total DNA measurements of each sample.
However a significant diﬀerence in ALP expression between
untreated and heat treated samples is only observed at
72 hours between the 37 °C and the 42 °C sample.
The total DNA measurements indicate that the heat-shock
treatment had a negative eﬀect on the cells, with their corres-
ponding total ALP production lower than that of the untreated
sample. However, the total ALP measurement does not take
into account the reduction in cell viability following hyperther-
mia treatments, as indicated in the data shown in Fig. 2 and
3a. In fact the ALP production normalized to the total DNA
content (proportional to the ALP produced by each live cell34),
Fig. 2 Bright ﬁeld images of MG-63 cells maintained at 37 °C (a–c) or exposed to two 30 min magnetic hyperthermia treatments in expansion
media: one at time point 0 hours and the second at 48 hours, reaching controlled temperatures of 42 °C (d–f ), or 47 °C (g–i) during each treatment.
Samples a, d and g were imaged at 24 hours; b, e and h were imaged at 72 hours and c, f and i at 120 hours, from the start of the experiment. Scale
bar is 100 μm.
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reveals a very diﬀerent picture (Fig. 3c). At 24 hours, there is
minimal ALP production per live cell in the 37, 42 and 47 °C
conditions with no significant diﬀerence between them. At
72 hours, an increase in the ALP/cell of the 42 °C sample is
found compared to the untreated 37 °C sample although this
doesn’t become significant until 120 hours. At 120 hours, the
expression of ALP/cell is significantly elevated for both
the heat-shock treated samples compared to the untreated
sample.
These results can also be appreciated qualitatively by
observing that the total ALP expressed by heat-shock treated
cells (Fig. 3b) shows a less dramatic reduction for increasing
time points than the corresponding live cell count (Fig. 3a).
Thus the surviving cells must have up-regulated their ALP
expression, as is shown quantitatively in Fig. 3c.
Discussion
The results shown here suggest that magnetic hyperthermia
can induce diﬀerentiation in cancer cells, in addition to redu-
cing cell viability. It could therefore be considered as an
alternative to current chemical based methods for inducing
diﬀerentiation in cancer therapy. To date, the most extensively
studied diﬀerentiation factor for CSC is all-trans-retinoic acid
which acts by triggering expression of diﬀerentiation-related
genes. However, the in vitro eﬃciency of retinoic acid to trigger
diﬀerentiation has not been replicated in vivo.35 In addition,
although it is generally well tolerated, it could lead to compli-
cations collectively referred to as the ‘retinoic acid
syndrome’.36
Bulk heating has previously been shown to trigger diﬀeren-
tiation in MG-63 cells.17 In the work by Shui & Scutt (2001),17
the cells were exposed to 1 hour heat treatment at diﬀerent
temperatures from 39 to 42.5 °C by placing them in a tempera-
ture-controlled water bath. The expression of ALP per 104 cells,
96 hours following the treatment, was found to linearly
increase with the treatment temperature. These results indi-
cate that temperature-triggered diﬀerentiation is not restricted
to magnetic hyperthermia. However, the advantage of mag-
netic hyperthermia in comparison to bulk heating would be
the ability to remotely target specific regions within a cell and
to apply localized heating at the cellular level without aﬀecting
neighbouring tissue.37
During hyperthermia treatment, at temperatures above a
threshold of 45 °C, cells predominantly undergo necrosis,
whilst they are more susceptible to undergo apoptosis below
this threshold.38,39 Triggering cell-death via apoptosis is pre-
ferred to necrosis as the latter can result in inflammation and
metastasis.40–42 In our study we found that both mild (42 °C)
and more extreme (47 °C) magnetic hyperthermia mediated
heat-shock had a significant impact on the viability of the
MG-63 cells, as seen by the DNA measurements. On the other
hand, the surviving cells express significantly higher levels of
ALP in both cases. The upregulation of ALP expression by the
surviving cells in the 42 °C sample indicates that it is possible
to trigger the diﬀerentiation of cancerous cells via magnetic
hyperthermia even at modest temperatures.
MG-63 cells, apart from being a good model cell line for
assessing various cancer therapies, are of additional interest
as they have been found to harbour a sub-population of cancer
stem cells (CD133+/Nestin).43–46 Although in this work the
eﬀect of hyperthermia has been studied on the population as a
whole, future studies can look at identifying the CSC and non-
CSC subpopulations of the MG-63 cells and investigating the
diﬀerential eﬀects of magnetic hyperthermia on each subtype.
This approach would be able to clearly define the responses of
these cells to heat and the potential of magnetic hyperthermia
as an alternative cancer diﬀerentiation therapy targeting CSCs.
In this initial study we have explored an early marker for
diﬀerentiation of osteosarcoma cells down the osteogenic
lineage. Further work is now needed to understand how MNP-
mediated heat-shock aﬀects long-term lineage commitment of
Fig. 3 Eﬀect of heat-shock treatment on the cell number and alkaline
phosphatase (ALP) expression: MG-63 cells exposed to temperatures of
37, 42 and 47 °C in expansion media for two 30 min treatments, one at
time point 0 hours and the second at time point 48 hours. Total DNA
content (a), total ALP content (b), and the normalised ALP/DNA (pro-
portional to ALP/cell) (c), were measured at 24, 72 and 120 hours. Error
bars represent standard error for n = 3 and line over columns indicates
groups that were signiﬁcantly diﬀerent from each other (Tukey test, p <
0.05) with the star indicating signiﬁcance.
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the surviving cells, as well the eﬀects of the combination of
duration and frequency of the heat treatment in diﬀerent cell
types and down diﬀerent lineages. However these results are
the first demonstration showing the potential of MNP-
mediated hyperthermia as a diﬀerentiation therapy. As heat is
only generated in the proximity of the MNPs, magnetic
hyperthermia is a local eﬀect and so should not adversely
influence healthy tissue surrounding the tumour. By functio-
nalizing the MNPs with CSC-specific markers which dis-
tinguish the CSCs from non-tumorigenic cells, an even more
targeted approach could be adopted. In addition, by combin-
ing traditional radio- or chemotherapy to target the non-CSC
population, together with MNP-mediated hyperthermia using
MNPs with higher heating potential47 to target the CSC popu-
lation, it may be possible to develop more eﬃcient and cura-
tive therapies for cancer treatment.
Conclusion
We investigated the eﬀect of magnetic hyperthermia on the
proliferative and diﬀerentiation state of the bone-cancer cell
line MG-63. Our results show that, apart from triggering heat-
related cell death, magnetic hyperthermia also provides an
additional stimulus to the surviving cells to further diﬀeren-
tiate to form a more mature phenotype. In addition, our study
shows that mild hyperthermia of 42 °C is suﬃcient to trigger
diﬀerentiation commitment, with such mild heat-shock likely
to trigger apoptosis rather than necrotic cell death. Further
work is needed to understand how MNP-mediated heat-shock
aﬀects long-term lineage commitment of the surviving cells in
diﬀerent cell types down diﬀerent lineages. However, the high
degree of localised temperature control possible with the mag-
netic hyperthermia technique, means that this method has
huge potential to be used as either an alternative or comp-
lementary approach to existing diﬀerentiation therapies.
Experimental section
Preparation and characterisation of MNP suspensions
The Zn0.4Fe2.6O4 MNPs were produced via microbial iron
reduction of zinc-doped ferrihydrite according to the methods
described in detail previously.48 Following this, the MNPs were
coated with citric acid to prepare stable aqueous suspensions
using procedures described in detail elsewhere.9,49 The sus-
pensions were sterilized using 0.2 μm filters prior to being
resuspended in cell-culture media for the hyperthermia experi-
ments. MNP suspension concentrations were measured using
the Ferrozine method for iron. Briefly, the nanoparticle sus-
pensions were digested in concentrated nitric acid (70%;
Sigma, UK) at high temperatures (>60 °C) overnight and were
treated with equal amounts of 6.6 M of the reducing agent
hydroxylamine hydrochloride (Sigma, UK) for 150 min at room
temperature. This reduces Fe(III) to Fe(II) as the Ferrozine assay
is specific for the latter.
To quantify the heating properties of the Zn0.4Fe2.6O4
MNPs, 1 ml of the aqueous suspensions were transferred to
1.5 ml centrifuge tubes. The tubes were placed in the centre of
a custom built magnetic hyperthermia instrument comprising
of a temperature-regulated coil capable of generating high-fre-
quency (50–1000 kHz) AC magnetic fields of up to 30 mT. By
using diﬀerent coil-capacitor combinations, diﬀerent field
strengths were attained. Water at a pre-set temperature was cir-
culated through the coil to prevent the coil from over-heating
and to regulate the non-magnetic heating of the sample. The
temperature was recorded in the sample space at the centre of
the coil by inserting an optical probe into the sample.
The specific loss power (SLP) was calculated using the
expression
SLP ¼ CVS
m
dT
dt
where C is the volumetric specific heat capacity of the sample
(Cwater = 4185 J L
−1 K−1), Vs is the sample volume, and m is the
mass of magnetic material in the sample. A plot of tempera-
ture vs. time was plotted and the slope of the initial linear
region of the heating curve, dT/dt was used to calculate the
SLP values based on equation.
Cell culture
MG-63 cells, an osteosarcoma cell line (Lonza, UK) were
expanded in T-flasks in expansion media consisting of 4.5 g
L−1 glucose Dulbecco’s Modified Eagle’s medium (Lonza, UK)
supplemented with 10% foetal bovine serum (FBS), 1% peni-
cillin/streptomycin (antibiotics and antimycotics) and 1%
L-glutamine to obtain required cell numbers.
PLA films were cut to required size (1 × 1 cm2) and sterilized
by soaking in 70% ethanol overnight followed by UV steriliza-
tion. They were rinsed well with phosphate buﬀered saline to
remove any remaining ethanol and soaked in expansion media
overnight in well plates. This step was done to promote for-
mation of a protein layer by the FBS and enhance cellular
attachment.
The cell suspensions were prepared via trypsinization, and
immediately seeded onto the PLA films in expansion media at
∼80% confluency and allowed to attach overnight. For the
heat-shock treatments, the 3 cell-seeded PLA films were
removed from the well plates and placed vertically into 5 ml
bijou tubes. A fourth empty film was placed in the tube for
stability. The MNP suspension was resuspended in HEPES
buﬀered DMEM medium (pH stable without gas regulation;
Gibco, UK) containing 20% FBS, 2% antibiotics/antimycotics,
1% L-glutamine and 1% non-essential amino acids at a con-
centration of 0.3 mg ml−1 (10% v/v). 1.5 ml of this solution
was added slowly into the tubes so as to not disturb the films
or cause shear stress to the cells and tubes were closed tight
with a screw cap.
In vitro magnetic hyperthermia
The closed tubes containing the PLA films were placed within
the coil of the magnetic hyperthermia instrument. The water
Nanoscale Communication
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cooling in the magnetic hyperthermia system coil was set at a
temperature that allowed the solution placed within the coil to
be maintained at 37 °C in the absence of MNP induced
heating. For the heat-shock treated samples, the cells were
exposed to 362 kHz and varying field strength (by adjusting
the applied voltage) to achieve the target temperatures. To
reach 42 °C, the voltage was set to 40 ± 5 V and current 10.2 ±
1.5 A. For 47 °C, the voltage was set to 51.1 V and the current
13 ± 0.2 A. Cells were maintained at the target temperatures
for 30 min at time 0 and for a second 30 min exposure at
48 hours. Temperature was measured using an optical temp-
erature probe. Following each treatment, the PLA films with
cells were immediately transferred to fresh well plates and
incubated in expansion media for further assays. Bright-field
images of the cells were taken at diﬀerent time points after
hyperthermia treatment, using an Olympus IX83 microscope
fitted with a camera using the Fluorview 10 software.
DNA and ALP quantification
At each time point, wells were washed with PBS to remove cell
debris and any secreted ALP to ensure that only the intracellu-
lar ALP was measured. This was followed by cell lysis using
0.1% Triton-X in water. Cell lysates were used for both ALP and
DNA assays. The total DNA concentration was quantified using
the Quanti-iT™ PicoGreen® dsDNA assay kit (ThermoFisher
Scientific, UK). In brief, 20 μl of cell lysate was mixed with
50 μl of 1× PicoGreen (PG) diluted in 1× TE buﬀer. Samples
were incubated with PG for 5 min at room temperature in the
dark. The fluorescence of PG is enhanced when bound to
double stranded DNA. The fluorescence intensities of the
samples following incubation were measured at excitation/
emission wavelengths of 485/530 nm on a BioTek synergy2
plate reader using the GEN 1.05 software.
Alkaline phosphatase expression
Total intracellular ALP content was measured via the 4-methyl-
umbelliferyl phosphate (4-MUP) Liquid Substrate System
(Sigma-Aldrich, UK). ALP cleaves the 4-MUP in alkaline con-
ditions to release the fluorescent product 4-MU. In brief, cell
lysates were incubated with equal volumes of 4-MUP reagent
for 30 min in the dark at 37 °C. Following this, the fluo-
rescence was measured in a plate reader (BioTek Instrument
Inc.) at excitation/emission wavelengths of 360/440 nm. For
normalizing to the number of cells, the total ALP content was
divided by the total DNA content for each sample.
Statistics
Each column in Fig. 3 represent the mean (n = 3) and the error
bars are the standard error of the mean. A one-way ANOVA was
performed in conjunction with Tukey post-hoc test between
samples at each time point as the data was shown to be nor-
mally distributed and having equal variance using the
Shapiro–Wilk and Levene’s test respectively.
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